Health Care • Biotechnology: Pharmaceutical Preparations
$0.65 ▲ +0.03
(+4.84%)
MKT CAP: $28.0M • VOL: 154.6K
52W L $0 52W H $19
CPHI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.1M | $4.5M | $7.0M |
| YoY Revenue Growth % | -8.5% | -35.4% | — |
| Gross Profit | -$131.9K | -$2.0M | — |
| Gross Margin % | -3.2% | -43.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.2M | -$4.6M | -$2.8M |
| Operating Margin % | -78.2% | -80.0% | -39.2% |
| Net Income (GAAP) | -$3.2M | -$4.7M | -$3.1M |
| EBITDA (Normalized) | -$3.2M | -$4.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $148.3K | -$406.1K | -$699.7K |
| Capital Expenditures (CapEx) | $59.3K | $38.4K | — |
| Free Cash Flow (FCF) | $88.9K | -$444.5K | -$699.7K |
| FCF Margin % | 2.1% | -9.8% | -10.0% |
| Return on Invested Capital (ROIC %) | -11.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $345.1K | $626.9K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $22.7M | $7.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CPHI.